| __timestamp | Halozyme Therapeutics, Inc. | Teva Pharmaceutical Industries Limited |
|---|---|---|
| Wednesday, January 1, 2014 | 22732000 | 9216000000 |
| Thursday, January 1, 2015 | 29245000 | 8296000000 |
| Friday, January 1, 2016 | 33206000 | 10044000000 |
| Sunday, January 1, 2017 | 31152000 | 11560000000 |
| Monday, January 1, 2018 | 10136000 | 10558000000 |
| Tuesday, January 1, 2019 | 45546000 | 9351000000 |
| Wednesday, January 1, 2020 | 43367000 | 8933000000 |
| Friday, January 1, 2021 | 81413000 | 8284000000 |
| Saturday, January 1, 2022 | 139304000 | 7952000000 |
| Sunday, January 1, 2023 | 192361000 | 8200000000 |
| Monday, January 1, 2024 | 159417000 | 8480000000 |
Igniting the spark of knowledge
In the evolving landscape of pharmaceuticals, understanding cost structures is crucial. From 2014 to 2023, Teva Pharmaceutical Industries Limited and Halozyme Therapeutics, Inc. have shown contrasting trends in their cost of revenue. Teva, a giant in the industry, saw its cost of revenue peak in 2017, reaching approximately 11.56 billion, before gradually declining to around 8.2 billion by 2023. This represents a reduction of about 29% over the period, indicating strategic cost management or shifts in operational focus.
Conversely, Halozyme's cost of revenue has surged, growing nearly eightfold from 22.7 million in 2014 to 192.4 million in 2023. This dramatic increase suggests significant expansion or investment in production capabilities. These trends highlight the diverse strategies employed by pharmaceutical companies in managing their operational costs, reflecting broader industry dynamics and individual company strategies.
Novo Nordisk A/S vs Halozyme Therapeutics, Inc.: Efficiency in Cost of Revenue Explored
Cost of Revenue Trends: Vertex Pharmaceuticals Incorporated vs Halozyme Therapeutics, Inc.
Analyzing Cost of Revenue: Teva Pharmaceutical Industries Limited and Corcept Therapeutics Incorporated
Cost Insights: Breaking Down Teva Pharmaceutical Industries Limited and Alkermes plc's Expenses
Comparing Cost of Revenue Efficiency: Bio-Techne Corporation vs Halozyme Therapeutics, Inc.
Cost Insights: Breaking Down Sarepta Therapeutics, Inc. and Halozyme Therapeutics, Inc.'s Expenses
Analyzing Cost of Revenue: Halozyme Therapeutics, Inc. and Pharming Group N.V.
Cost of Revenue: Key Insights for Halozyme Therapeutics, Inc. and PTC Therapeutics, Inc.
Cost of Revenue Comparison: Halozyme Therapeutics, Inc. vs ACADIA Pharmaceuticals Inc.
Cost Insights: Breaking Down Halozyme Therapeutics, Inc. and Mesoblast Limited's Expenses
Halozyme Therapeutics, Inc. vs Galapagos NV: Efficiency in Cost of Revenue Explored
Comparing Cost of Revenue Efficiency: Halozyme Therapeutics, Inc. vs MiMedx Group, Inc.